AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

The Skin as a Window to the Central Nervous System in Frontotempolar Lombar Degeneration

RecruitingNAAges 50 Years - 75 YearsAllNantes University Hospital
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Frontotemporal lobar degeneration (FTLD) is a clinically heterogeneous syndrome, characterized by progressive decline in behaviour and/or language. From a pathological standpoint, like the great majority of neurodegenerative disorders, FTLD are proteinopathies, which are characterized by the presence of specific protein deposits in the Central Nervous System (CNS). Accordingly, the two main deposits observed in FTLD are either made of Tau or transactive response DNA binding protein 43 (TDP-43). In pathological conditions such as FTLD, both proteins are aggregated and hyperphosphorylated. It is now well established that the pathological process in some proteinopathies such as synucleinopathies (of which Parkinson's disease is the main representative) is not limited to the brain but also widespread throughout the peripheral autonomic networks, including the autonomic innervation of the s

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria (patients): * Adressed or followed at memory clinic or ALS expert center at Nantes university hospital. * Aged 50-75 years * Fulfilling current diagnosis criteria for one of the disorder: vcfFTD, non-Alzheimer PPA (semantic or non fluent), DCB or PSP,ALS * MMSE โ‰ฅ 18 * Membership of social security scheme Inclusion Criteria (healthy volunteers): * No history of neurological disease, diabetes, or alteration/damage of peripheral nervous system * Aged 50-75 years Paired to at least one patient on age (less or more 5 years) * MOCA โ‰ฅ 26 * Membership of social security scheme Non inclusion Criteria (Patients and healthy volunteers): * Concomitting conditions affecting the peripheral nervous system such as but not limited to diabetes, renal failure, thyroid disorder, vitamin B12 deficiency, acute and chronic inflammatory diseases HIV, syphilis * Know allergy to local anesthetic * Known coagulopathy * Pregnant women or breastfeeding women * Person under court protection sous sauvegarde de justice * Person under guardianship * Inability to sign an informed consent Non inclusion criteria (Patients) โ€ข Patient with neurological disease other than FTLD Non inclusion criteria (Healthy volunteers) : โ€ข Evidence of neurological disorder at the inclusion including but not limted to FTLD, Parkinson disease, Alzheimer disease, lewy body dementia, Huntington disease, systemic lupus erythematosus multiple sclerosis; learning disabilities, mental retardation, severe hypoxic brain injuries, brain trauma with permanent cognitive impairments.
๐Ÿ’Š

What it tests

  • Skin biopsy
๐Ÿ“

Where

1 site
Nantes University Hospital
Nantes, France
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy